2013
DOI: 10.1038/aja.2013.16
|View full text |Cite
|
Sign up to set email alerts
|

Clinical outcomes in patients with stage I non-seminomatous germ cell cancer

Abstract: This study assesses the long-term outcomes in Han Chinese patients with clinical stage I non-seminomatous germ cell testicular cancer (CSI NSGCT) treated with surveillance, retroperitoneal lymph node dissection (RPLND) and adjuvant chemotherapy. We retrospectively evaluated 89 patients with a mean age of 26.5 years. After orchiectomy, 37 patients were treated with surveillance, 34 underwent RPLND and 18 were managed with chemotherapy. The overall survival rate, the recurrence-free survival rate and the risk fa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 27 publications
0
7
0
Order By: Relevance
“…Both regimens are category 1 recommendations, and either is preferable to initial RPLND because these patients nearly always have disseminated disease. 82,83…”
Section: Primary Treatment Of Nonseminoma Stage Ismentioning
confidence: 99%
“…Both regimens are category 1 recommendations, and either is preferable to initial RPLND because these patients nearly always have disseminated disease. 82,83…”
Section: Primary Treatment Of Nonseminoma Stage Ismentioning
confidence: 99%
“…Either 3 cycles of BEP or 4 cycles of EP are preferable treatments because the majority of these patients have disseminated disease. [15][16][17] Thus if the tumor markers remain high after orchiectomy; adjuvant chemotherapy remains the hallmark of treatment. After chemotherapy, tumor markers should be assessed until they are normal, as long as they follow their half-life kinetics and no metastases are revealed.…”
Section: Discussionmentioning
confidence: 99%
“…Semen analysis and sperm banking should be offered for all young males before chemotherapy. [11][12][13][14][15][16][17][18][19][20] A testicular prosthesis could be implanted in the scrotum, to provide a normal look. The prosthesis approved for use in the United States is filled with saline (saltwater) and comes in different sizes to match the remaining testicle.…”
Section: Discussionmentioning
confidence: 99%
“…There are no prospective randomized controlled trials comparing carboplatin monotherapy with surveillance in CSI SE patients. Survival data and recurrence rates after adjuvant carboplatin therapy are only available from multi-arm [14] 2017 Retrospective cohort study 2 × BEP 1992-2017 184 1.1% Ondrus [15] 2015 Prospective cohort study 2 × BEP 1992-2014 167 1.2% Kobayashi [12] 2013 Retrospective cohort study 1980-2008 4 0% Lv [16] 2013 Retrospective cohort study 2 × BEP 1997-2011 18 5.6% Tandstad [17] 2010 RCT prospective cohort studies and from a large number of retrospective single-arm studies. Concerning disease free survival, the 3 years' disease free rate after two courses of carboplatin monotherapy is 98.0% (95% CI 94.0-100%) [30].…”
Section: Carboplatin Chemotherapy Versus Surveillancementioning
confidence: 99%